Subject(s)
Medical Oncology , Oncology Service, Hospital/organization & administration , Antineoplastic Agents/economics , Antineoplastic Agents/therapeutic use , Drug Costs , Evidence-Based Medicine , Humans , Hungary , Internship and Residency/methods , Medical Oncology/methods , Medical Oncology/trends , Oncology Service, Hospital/economics , Oncology Service, Hospital/trends , Radiation Oncology/methods , Radiation Oncology/trends , Societies, MedicalSubject(s)
Cancer Care Facilities/organization & administration , Medical Oncology , Neoplasms/therapy , Oncology Service, Hospital/organization & administration , Cancer Care Facilities/economics , Humans , Hungary , Medical Oncology/organization & administration , Neoplasms/drug therapy , Neoplasms/radiotherapy , Neoplasms/rehabilitation , Neoplasms/surgery , Oncology Service, Hospital/economics , Rehabilitation/methods , Rehabilitation/organization & administration , Societies, Medical , WorkforceABSTRACT
UNLABELLED: Authors presented data of treatment results and course of disease in 487 ovarian cancer patients treated by primary surgery and paclitaxel-carboplatin combination chemotherapy between July 1, 2002 and December 31, 2003. PATIENTS: Most of our patients (87.8%) belonged to the age-group between 40-70 years. Distribution of their histological diagnosis was as 69.6% serous, 10.7% mucinous, 5.1% endometrial and 4.7% undifferentiated carcinoma. The grade distribution was found as 8.4% grade 1, 40.9% grade 2 and 35.9% grade 3. RESULTS: The primary surgery was evaluated as optimal in 41.7%, suboptimal in 37.3% and exploration was performed in 21.1%. Most patients started chemotherapy 20 days after surgery and 74.2% of them got six courses. During the evaluation period 61 intervallum laparotomies were performed, and resulted on 55.7% optimal debulking. Complete remission was found in 58.9%, and partial remission in 14.7% of patients. This treatment resulted on a complete remission in 40.9% at the follow-up of 12 months.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma/therapy , Ovarian Neoplasms/therapy , Ovariectomy , Adenocarcinoma, Mucinous/therapy , Adult , Aged , Brenner Tumor/therapy , Carboplatin/administration & dosage , Carcinoma/drug therapy , Carcinoma/epidemiology , Carcinoma/pathology , Carcinoma/surgery , Carcinoma, Endometrioid/therapy , Chemotherapy, Adjuvant , Cystadenocarcinoma, Serous/therapy , Drug Administration Schedule , Female , Humans , Hungary/epidemiology , Middle Aged , Ovarian Neoplasms/drug therapy , Ovarian Neoplasms/epidemiology , Ovarian Neoplasms/pathology , Ovarian Neoplasms/surgery , Paclitaxel/administration & dosage , Retrospective Studies , Treatment OutcomeABSTRACT
Data on the first-line treatment of ovarian cancer in special centers of Hungary 2002 and 2003 are presented, involving 283 and 416 patients, respectively. Patients' age, clinical stage and histological type of the tumor were highly similar to literature data, while grades were different. Surgical effectiveness in case of IIIc staged tumors with >1 cm residual mass was 37%. The ratio of interval laparotomy was about 15%. Overall response rates of the first-line treatment of ovarian cancer was 82%, while the rate of complete remissions was 60%. The authors provide detailed analysis of factors that can improve the chemotherapy of ovarian cancer in Hungary.
